GOVERNMENT OF THE DISTRICT OF COLUMBIA  
Department of Health Care Finance  

Office of the Senior Deputy Director/Medicaid Director  
Transmittal # 22-07  

TO:  All DC Medicaid Providers  
FROM:  Melisa Byrd  
        Senior Deputy Director and State Medicaid Director, DHCF  
DATE:  February 17, 2022  
SUBJECT:  Professional Services Billing Code and Reimbursement Rate for Newly Approved Antiviral Therapy  
           Billing Code for COVID-19, Remdesivir  

---  

Purpose  
The Department of Health Care Finance (DHCF) is committed to taking critical steps to ensure District residents have access to treatments for COVID-19 in the professional setting. This transmittal provides notice of coverage and reimbursement for the antiviral drug therapy, remdesivir, in the professional fee schedule for fee-for-service providers that bill HCPCS and CPT codes on CMS-1500 claim forms, and for providers enrolled in Medicaid Managed Care Organization (MCO) networks.  

Intravenous remdesivir is approved by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adult and pediatric patients (aged ≥12 years and weighing ≥40 kg). It is also available through an FDA Emergency Use Authorization (EUA) for the treatment of COVID-19 in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg. Remdesivir should be administered in a hospital or a health care setting that can provide a similar level of care to an inpatient hospital. DHCF added the code to the professional fee schedule for any such health care settings providing a similar level of care.  

Billing Codes & Reimbursement  
The billing and reimbursement rates for administration of antiviral drug therapy for COVID-19 are based on the published guidance by CMS. If newer rates are published by CMS or a Medicare Administrator Contractor (MAC), the rates may be updated with retroactive payment adjustments as necessary.  

Administration  
Providers should report the typical administration billing codes for the intravenous administration based on the type and total time of the infusion.
Product
HCPCS billing code J0248 has been created to specify the product of remdesivir. Providers should bill according to the units and dosage administered.

<table>
<thead>
<tr>
<th>HCPCS/</th>
<th>Description</th>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Effective Date</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0248</td>
<td>Inj, remdesivir, 1 mg</td>
<td>Veklury</td>
<td>remdesivir</td>
<td>12/23/2021</td>
<td>$5.51</td>
</tr>
</tbody>
</table>

For MCO Enrollees: Providers should follow instructions provided by the enrollee’s MCO for billing for COVID-19 antiviral therapy. MCOs are required to reimburse providers at the rates published in this transmittal. Contact the appropriate MCO for more information:

- AmeriHealth Caritas DC Provider Services: 202-408-2237 or 1-888-656-2383
- CareFirst Community Health Plan DC Provider Services: 202-821-1100
- Health Services for Children with Special Needs (HSCSN) Provider Services: 202-467-2737 | Option #2
- MedStar Family Choice-DC Provider Services: 855-798-4244

Contact
Please refer to the DHCF provider fee schedule available at [https://www.dc-medicaid.com](https://www.dc-medicaid.com) for all future updates related to coverage of COVID-19 codes, and for the most up-to-date information on pricing. If you have questions, please contact Amy Xing, Reimbursement Analyst, at amy.xing2@dc.gov or 202-481-3375.

Cc: DC Hospital Association
    DC Primary Care Association
    DC Health Care Association
    DC Home Heath Association
    DC Behavioral Health Association
    DC Coalition of Disability Service Providers
    Medical Society of DC